Short answer
Strata Critical Medical, Inc. (SRTA) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $73M (up 2.4% year over year) with net income of −$11M.
Q2 2026 key financials · XBRL
- Revenue
- $73M
- +2.4% YoY · +7.6% QoQ
- Net income
- −$11M
- −181.0% YoY · −588.2% QoQ
- Operating margin
- -7.5%
- Gross margin
- 21.0%
- EPS (diluted)
- −$0.13
- −160.0% YoY · −533.3% QoQ
Source: XBRL data from the Strata Critical Medical, Inc. (SRTA) Q2 2026 10-Q on SEC EDGAR. USD.
Strata Critical Medical, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue and YoY change not provided in supplied MD&A excerpt
- Profitability and margin percentages not provided in supplied MD&A excerpt
- Segment performance unavailable; Logistics and Clinical segment descriptions only
- Passenger sale generated $70.2M net proceeds; additional consideration up to $35.0M
- 2026 acquisitions totaled $39.2M upfront cash consideration; donor supply flattening flagged as headwind
Risk Factors
- No material risk-factor changes from December 31, 2025 Form 10-K
- Trading-price risk from business results differing materially from expectations
- Forward-looking-statement risk from actual results differing materially from projections
- Acquisition-related equity issuance: 742,060 shares issued for HLT-NRP on June 24, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Strata Critical Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.